期刊文献+

Survivin的表达及相关临床因素与胃癌预后的关系

下载PDF
导出
摘要 目的:研究生存蛋白(Survivin)在胃癌组织中是如何进行表达的和各临床病理因素对其预后的影响。方法:利用免疫组化法检测50例胃癌组织Survivin的表达以及"Kaplan-Meier单因素分析法"研究各临床病理因素和胃癌组织存活长短之间的关系,应用Cox比例风险回归模型对生存期的影响因素进行回归分析。结果:50例胃癌组织中Survivin阳性率为74%,单因素分析50例患者的生存时间与TNM分期、Bormann分型、肿瘤侵润深度和Survivin表达有关,Cox比例风险回归模型分析临床分期、Bormann分型和Survivin是影响预后的最危险因素之一。结论:对胃癌预后存在威胁的因素包括:"Survivin、临床分期以及Bormann分型",并具有各自的独立性。
出处 《陕西医学杂志》 CAS 2015年第8期1087-1088,共2页 Shaanxi Medical Journal
基金 陕西省社会发展科技攻关项目(20145SF-221)
  • 相关文献

参考文献8

二级参考文献71

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition [ J ]. Gastric Cancer, 2011, 14(2) :101 -112.
  • 3Chau I,Norman AR,Cunningham D,et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophagogastric cancer-pooled analysis from three multicenter, randomized ,controlled trials using individual patient data [ J ]. J Clin Oncol,2004,22(12) :2395 -2403.
  • 4Kodera Y,Ito Y,Ohashi N, et al. Impact of clinical response to first-line chemotherapy on gastric cancer patients treated with second-line and third-line chemotherapy [ J ]. Hepatogastroenterolo-gy, 2011, 58(107-108) :1041 -1045.
  • 5Cidon EU, Centeno RG, Lagarto EG, et al. HER-2 evaluation in a specific gastric cancer population with the highest rate of mortality in Spain [ J ]. J Clin Oncol, 2011 [2012-3-5]. http://www. hindawi. com/journals/jo/2011/391564/.
  • 6Rose JS, Bekaii-Saab TS. New developments in the treatment of metastatic gastric cancer: focus on trastuzumab[ J]. Onco Targets Ther,2011,4:21 -26.
  • 7Ohtsu A, Yoshida S, Saijo N, et al. Disparities in gastric cancer chemotherapy between the East and West [ J ]. J Clin Oncol, 2006,24(14) :2188 -2196.
  • 8Ohtsu A, Shah MA,Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase HI study [J]. J Clin Oncol,2011, 29(30) :3968 -3976.
  • 9Price TJ,Shapiro JD,Segelov E,et al. Management of advanced gastric cancer [ J ]. Expert Rev Gastroenterol Hepatol,2012,6 (2) :199 -209.
  • 10Bang YJ, Van Custsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophage-al junction cancer (ToGA) : a phsae 3,open-label, randomised controlled trial[ J]. Lancet, 2010 , 376(9742) : 687 - 697.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部